Biological roles of trace elements in the brain with special focus on Zn and Fe;Rôles biologiques des éléments traces dans le cerveau - Exemples du Zn et du Fe

Revue Neurologique

Volumn 167, Issue 4, 2011, Pages 269-279

  Bohic, S ^a,b   Ghersi Egea, J F ^c   Gibon, J ^b,d   Paoletti, P ^e   Arnaud, J ^f,g   Hunot, S ^h   Boom, A ⁱ   Bouron, A ^b,d  

^a GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^b UNIV GRENOBLE ALPES   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CEA GRENOBLE   (France)

^e PSL RESEARCH UNIVERSITY   (France)

^f INSERM   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

ⁱ UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Brain; Iron; Manganese; Metals; Neurodegeneration; Neurological diseases; Zinc

Indexed keywords

IRON; ZINC;

ALZHEIMER DISEASE; BRAIN; COGNITION; HUMAN; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SYNAPTIC TRANSMISSION;

EID: 79954424540     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2010.07.035     Document Type: Review

References (97)

1. Allen DD, Orvig C, Yokel R. Evidence for energy-dependent transport of aluminum out of brain extracellular fluid. Toxicology 1995;98:31-9.
2. Allen DD, Yokel RA. Dissimilar aluminum and gallium permeation of the blood-brain barrier demonstrated by in vivo microdialysis. J Neurochem 1992;58:903-8.
3. Aschner M, Guilarte TR, Schneider JS, Zheng W. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol 2007;221:131-47. (Pubitemid 46779052)
4. Azimi S, Rocher V, Muller M, Moilleron R, Thevenot DR. Sources, distribution and variability of hydrocarbons and metals in atmospheric deposition in an urban area (Paris, France). Sci Total Environ 2005;337:223-39.
5. Babady NE, Carelle N, Wells RD, Rouault TA, Hirano M, Lynch DR, et al. Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments. Mol Genet Metab 2007;92:23-35. (Pubitemid 47361887)
6. Bartzokis G, Tishler TA, Lu PH, Villablanca P, Altshuler LL, Carter M, et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 2007;28:414-23. (Pubitemid 46177391)
7. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005. (Pubitemid 34640761)
8. Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA study. Étude du vieillissement arteriel. J Am Geriatr Soc 2000;48:1285-91.
9. Bock NA, Paiva FF, Nascimento GC, Newman JD, Silva AC. Cerebrospinal fluid to brain transport of manganese in a non-human primate revealed by MRI. Brain Res 2008;1198:160-70.
10. Bohic S, Murphy K, Paulus W, Cloetens P, Salome M, Susini J, et al. Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. Anal Chem 2008;80:9557-66.
11. Bondier JR, Michel G, Propper A, Badot PM. Harmful effects of cadmium on olfactory system in mice. Inhal Toxicol 2008;20:1169-77.
12. Boom A, Authelet M, Dedecker R, Frederick C, Van Heurck R, Daubie V, et al. Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells. Biochim Biophys Acta 2009;1793:1058-67.
13. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
14. Bradbury MW, Deane R. Permeability of the blood-brain barrier to lead. Neurotoxicology 1993;14:131-6.
15. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003;26:207-14. (Pubitemid 36412003)
16. Carmona A, Deves G, Roudeau S, Cloetens P, Bohic S, Ortega R. Manganese accumulates within golgi apparatus in dopaminergic cells as revealed by synchrotron X-ray fluorescence nanoimaging. ACS Chem Neurosci 2010;1:193-203.
17. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76. (Pubitemid 32607332)
18. Choi BS, Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res 2009;1248:14-21.
19. Cole TB, Robbins CA, Wenzel HJ, Schwartzkroin PA, Palmiter RD. Seizures and neuronal damage in mice lacking vesicular zinc. Epilepsy Res 2000;39:153-69. (Pubitemid 30089587)
20. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909. (Pubitemid 37130207)
21. Deane R, Zheng W, Zlokovic BV. Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J Neurochem 2004;88:813-20. (Pubitemid 38199301)
22. Denhez F. Les pollutions invisibles. Delachaux et Niestlé, 2007.
23. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114(Pt 4):1953-75.
24. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-6. (Pubitemid 19140770)
25. Dries DR, Yu G. Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease. Curr Alzheimer Res 2008;5:132-46. (Pubitemid 351536338)
26. Faucheux BA, Hauw JJ, Agid Y, Hirsch EC. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. Brain Res 1997;749:170-4.
27. Faucheux BA, Hirsch EC, Villares J, Selimi F, Mouatt-Prigent A, Javoy-Agid F, et al. Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 1993;60:2338-41. (Pubitemid 23148814)
28. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 2003;86:1142-8. (Pubitemid 37022190)
29. Faucheux BA, Martin ME, Beaumont C, Hunot S, Hauw JJ, Agid Y, et al. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem 2002;83:320-30. (Pubitemid 35191397)
30. Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci U S A 1995;92:9603-7.
31. Fillebeen C, Ruchoux MM, Mitchell V, Vincent S, Benaissa M, Pierce A. Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res 2001;96:103-13. (Pubitemid 33145370)
32. Frederickson CJ, Suh SW, Silva D, Thompson RB. Importance of zinc in the central nervous system: the zinc-containing neuron. J Nutr 2000;130:1471S-83S.
33. Gao S, Jin Y, Hall KS, Liang C, Unverzagt FW, Ji R, et al. Selenium level and cognitive function in rural elderly Chinese. Am J Epidemiol 2007;165:955-65. (Pubitemid 46536659)
34. Ghersi-Egea JF, Monkkonen KS, Schmitt C, Honnorat J, Fevre- Montange M, Strazielle N. Blood-brain interfaces and cerebral drug bioavailability. Rev Neurol (Paris) 2009;165:1029-38.
35. Gielen M, Le Goff A, Stroebel D, Johnson JW, Neyton J, Paoletti P. Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition. Neuron 2008;57:80-93.
36. Goedert M, Spillantini MG. Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. Biochim Biophys Acta 2000;1502:110-21. (Pubitemid 30433860)
37. Golub MS, Keen CL, Gershwin ME, Hendrickx AG. Developmental zinc deficiency and behavior. J Nutr 1995;125:2263S-71S.
38. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45:1138-43.
39. Hahn P, Song Y, Ying GS, He X, Beard J, Dunaief JL. Age-dependent and gender-specific changes in mouse tissue iron by strain. Exp Gerontol 2009;44:594-600.
40. Hernandez L, Probst A, Probst JL, Ulrich E. Heavy metal distribution in some French forest soils: evidence for atmospheric contamination. Sci Total Environ 2003;312:195-219. (Pubitemid 36840916)
41. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991;56:446-51. (Pubitemid 21901982)
42. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72:355-63. (Pubitemid 26111202)
43. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:583-95. (Pubitemid 38844879)
44. Ilback NG, Lindh U, Minqin R, Friman G, Watt F. Iron and copper accumulation in the brain of coxsackievirus-infected mice exposed to cadmium. Environ Res 2006;102:308-13. (Pubitemid 44548547)
45. Inserm, 1999. Plomb dans l'environnement : quels risques pour la santé? Expertise collective Inserm, 1999.
46. Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, et al. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 2003;60:235-9. (Pubitemid 36152015)
47. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003;37:899-909. (Pubitemid 36398297)
48. Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol 1993;142:1574-85. (Pubitemid 24058144)
49. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D. Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 2005;113:1230-3. (Pubitemid 41387665)
50. Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, et al. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 2009;284:29065-76.
51. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A 2002;99:7705-10. (Pubitemid 34568755)
52. Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM, Hof PR. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 1994;650:20-31. (Pubitemid 24207040)
53. Li GJ, Choi BS, Wang X, Liu J, Waalkes MP, Zheng W. Molecular mechanism of distorted iron regulation in the blood-CSF barrier and regional blood-brain barrier following in vivo subchronic manganese exposure. Neurotoxicology 2006;27:737-44. (Pubitemid 44232984)
54. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403-9.
55. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007;30:317-37. (Pubitemid 47224759)
56. Malenka RC, Nicoll RA. Long-term potentiation - a decade of progress? Science 1999;285:1870-4.
57. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994;36:876-81. (Pubitemid 24370927)
58. Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol 2001;158:1345-54. (Pubitemid 32281298)
59. Molina-Holgado F, Hider RC, Gaeta A, Williams R, Francis P. Metals ions and neurodegeneration. Biometals 2007;20:639-54. (Pubitemid 46776561)
60. Morris CM, Edwardson JA. Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 1994;3:277-82.
61. Mulero V, Brock JH. Regulation of iron metabolism in murine J774 macrophages: role of nitric oxide-dependent and - independent pathways following activation with gamma interferon and lipopolysaccharide. Blood 1999;94:2383-9. (Pubitemid 29467686)
62. Ortega R, Cloetens P, Deves G, Carmona A, Bohic S. Iron storage within dopamine neurovesicles revealed by chemical nano-imaging. PLoS ONE 2007;2:e925.
63. Palmiter RD, Cole TB, Quaife CJ, Findley SD. ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci U S A 1996;93:14934-9. (Pubitemid 26419073)
64. Paoletti P, Ascher P, Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 1997;17:5711-25. (Pubitemid 27310487)
65. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007;7:39-47. (Pubitemid 46238036)
66. Paoletti P, Vergnano AM, Barbour B, Casado M. Zinc at glutamatergic synapses. Neuroscience 2009;158:126-36.
67. Persson E, Henriksson J, Tallkvist J, Rouleau C, Tjalve H. Transport and subcellular distribution of intranasally administered zinc in the olfactory system of rats and pikes. Toxicology 2003;191:97-108. (Pubitemid 37336536)
68. Persson E, Henriksson J, Tjalve H. Uptake of cobalt from the nasal mucosa into the brain via olfactory pathways in rats. Toxicol Lett 2003;145:19-27. (Pubitemid 38366126)
69. Puccio H. Multicellular models of Friedreich ataxia. J Neurol 2009;256(Suppl. 1):18-24.
70. Qian ZM, Shen X. Brain iron transport and neurodegeneration. Trends Mol Med 2001;7:103-8. (Pubitemid 32201671)
71. Rajan MT, Jagannatha Rao KS, Mamatha BM, Rao RV, Shanmugavelu P, Menon RB, et al. Quantification of trace elements in normal human brain by inductively coupled plasma atomic emission spectrometry. J Neurol Sci 1997;146:153-66. (Pubitemid 27112835)
72. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 1995;37:211-7.
73. Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, et al. Elevated cortical zinc in Alzheimer disease. Neurology 2006;67:69-75. (Pubitemid 44305464)
74. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A 2008;105:18578-83.
75. Sandstead HH. A brief history of the influence of trace elements on brain function. Am J Clin Nutr 1986;43:293-8. (Pubitemid 16099813)
76. Schweizer U, Brauer AU, Kohrle J, Nitsch R, Savaskan NE. Selenium and brain function: a poorly recognized liaison. Brain Res Brain Res Rev 2004;45:164-78. (Pubitemid 38802869)
77. Sensi SL, Paoletti P, Bush AI, Sekler I. Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 2009;10:780-91.
78. Smorgon C, Mari E, Atti AR, Dalla Nora E, Zamboni PF, Calzoni F, et al. Trace elements and cognitive impairment: an elderly cohort study. Arch Gerontol Geriatr Suppl 2004;9:393-402. (Pubitemid 38822890)
79. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
80. Song N, Wang J, Jiang H, Xie J. Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. Free Radic Biol Med 2010;48:332-41.
81. Stoltenberg M, Bruhn M, Sondergaard C, Doering P, West MJ, Larsen A, et al. Immersion autometallographic tracing of zinc ions in Alzheimer beta-amyloid plaques. Histochem Cell Biol 2005;123:605-11. (Pubitemid 41126079)
82. Strazielle N, Ghersi-Egea JF. Choroid plexus in the central nervous system: biology and physiopathology. J Neuropathol Exp Neurol 2000;59:561-74. (Pubitemid 30457787)
83. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000;852:274-8. (Pubitemid 30035163)
84. Sunderman Jr FW. Nasal toxicity, carcinogenicity, and olfactory uptake of metals. Ann Clin Lab Sci 2001;31:3-24.
85. Tarohda T, Yamamoto M, Amamo R. Regional distribution of manganese, iron, copper, and zinc in the rat brain during development. Anal Bioanal Chem 2004;380:240-6.
86. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008;283:29615-9.
87. Tournier BB, Frelon S, Tourlonias E, Agez L, Delissen O, Dublineau I, et al. Role of the olfactory receptor neurons in the direct transport of inhaled uranium to the rat brain. Toxicol Lett 2009;190:66-73.
88. Tratner I. Children lead poisoning: what progress in 20 years? Med Sci (Paris) 2003;19:873-7.
89. Trocello JM, Chappuis P, Chaine P, Remy P, Debray D, Duclos-Vallee JC, et al. Wilson disease. Presse Med 2009;38:1089-98.
90. Tu P, Gibon J, Bouron A. The TRPC6 channel activator hyperforin induces the release of zinc and calcium from mitochondria. J Neurochem 2010;112:204-13.
91. Vogt K, Mellor J, Tong G, Nicoll R. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron 2000;26:187-96.
92. Wang J, Jiang H, Xie JX. Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci 2007;25:2766-72. (Pubitemid 46888831)
93. Wright RO, Baccarelli A. Metals and neurotoxicology. J Nutr 2007;137:2809-13. (Pubitemid 350255318)
94. Xu X, Wang Q, Zhang M. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 2008;40:35-42.
95. Zatta P, Drago D, Bolognin S, Sensi SL. Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 2009;30:346-55.
96. Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001;76:1766-73. (Pubitemid 32221116)
97. Zheng W, Aschner M, Ghersi-Egea JF. Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol 2003;192:1-11. (Pubitemid 37205113)